

Enantioselective vinylogous Mukaiyama aldol reaction of α -ketoesters under bifunctional organocatalysis

Roberto del Río-Rodríguez,^a Víctor Laina-Martín,^a Jose A. Fernández-Salas,^{a,b*}
and José Alemán^{a,b*}

a. Departamento de Química Orgánica (Módulo 1), Facultad de Ciencias, Universidad Autónoma de Madrid, 28049-Madrid, Spain. E-mail: jose.aleman@uam.es; j.fernandez@uam.es; webpage: www.uam.es/jose.aleman

b. Institute for Advanced Research in Chemical Sciences (IAdChem), Facultad de Ciencias, Universidad Autónoma de Madrid, 28049-Madrid, Spain.

1. General methods and starting materials	2
2. Optimization table.....	3
3. General procedure A: Addition of silyl dienol ethers to α -ketoesters	5
4. General procedure B: Synthesis of biologically active derivatives.....	14
4.1. Antifungal δ -lactone analog (7)	14
4.2. Inhibitor of neuropathic pain (10)	16
5. NMR spectra and SFC chromatograms	18
6. Single Crystal X-Ray Structure of δ -lactone 7	64

1. General methods and starting materials

All dry solvents were dried using activated 4Å molecular sieves and stored under nitrogen. 4Å molecular sieves, 1.6-2.5 mm of particle size, were activated by microwave (700W) (3 x 60 sec) and subsequent cycles of vacuum/nitrogen. Substrates **1a-g**, **1i**, **1l**, **1m**, **1p-q**, as well as catalyst **3a** and **3b**, were acquired from commercial sources. Catalysts **3c-f** and α -ketoesters **1h**, **1j**, **1k**, **1n** were synthesized following a procedure described in the literature.¹ (Buta-1,3-dien-1-yloxy)trimethylsilane (**2a**) was acquired from commercial sources as a 70:30 *E*:*Z* mixture. (*Z*)-trimethyl((3-methylbuta-1,3-dien-1-yl)oxy)silane (**2b**) was synthesized following a procedure described in the literature.² For thin layer chromatography (TLC), silica gel plates with fluorescence indicator 254 nm were used and compounds were visualized by irradiation with UV light and/or by treatment with a solution of potassium permanganate in water followed by heating. Flash column chromatography was performed using Geduran® Silica Gel 60 (0.040-0.063 nm). Cyclohexane and ethyl acetate for flash chromatography were acquired from commercial sources and were used without previous purification. Optical rotation was recorded in cells with 10 cm path length; the specific solvents and concentrations (in g/100 mL) are indicated. NMR spectra were acquired on a *Bruker Avance 300 MHz spectrometer*, running at 300 and 75 MHz for ¹H and ¹³C, respectively. ¹⁹F-NMR spectra was acquired on a *Bruker Avance 500 MHz spectrometer*, running at 471 MHz. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CDCl₃, 7.26 ppm for ¹H-NMR and 77.2 ppm for ¹³C-NMR). ¹³C-NMR was acquired on a broad band decoupled mode. The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), bs (broad singlet). Electrospray ionization has been used for measuring the exact mass (indicated for each case): MS (ESI) (Electrospray ionization mass spectroscopy) was acquired with an *Agilent Technologies 6120 Quadrupole LC/MS*. In this technique, *MassWorks software ver. 4.0.0.0 (Cerno Bioscience)* was used for the formula identification. *MassWorks* is a MS calibration software which calibrates for isotope profile as well as for mass accuracy, allowing highly accurate comparisons between calibrated and theoretical spectra.³

¹ Catalyst synthesis: a) C. Cassani, R. Martín-Rapún, E. Arceo, F. Bravo and P. Melchiorre, *Nature Protocols* 2013, **8**, 325-344; α -ketoester synthesis: b) J. Zhuang, C. Wang, F. Xie, W. Zhang, *Tetrahedron* 2009, **65**, 9797-9800.

² M. Frías, R. Mas-Ballesté, S. Arias, C. Alvarado, J. Alemán, *J. Am. Chem. Soc.* 2017, **139**, 672-679.

³ a) Y. Wang and M. Gu, *Anal. Chem.* 2010, **82**, 7055-7062; b) Y. Wang, Methods for Operating MS Instrument Systems, United States Patent No. 6,983,213, **2006**; c) N. Ochiaia, K. Sasamoto, K. MacNamara *Journal of Chromatography A* 2012, **1270**, 296-304; d) H. Ho, R. Lee, C. Chen, S. Wang, Z. Li and M. Lee, *Rapid Commun. Mass Spectrom.* 2011, **25**, 25-32.

Enantiomeric excess was determined in a Supercritical Fluid Chromatography (SFC) with chiral columns. The chromatograms were acquired with an *Agilent Technologies 1260 Infinity* with a *SFC module* and a UV-vis detector. The chiral columns used were: Chiraldak IA, IB-3, IC, ID-3, IG-3 (see in each case).


2. Optimization table

Entry ^a	Catalyst	Solvent	Solvent amount (mL)	H ₂ O (equiv.)	Yield (%)	ee (%) ^b
1	3a	DCM	0.3	3	30	-78
2	3b	DCM	0.3	3	26	23
3	3c	DCM	0.3	3	19	-79
4	3d	DCM	0.3	3	29	89
5	3e	DCM	0.3	3	36	93
6	3f	DCM	0.3	3	27	-91
7	3e	DCE	0.3	3	21	91
8	3e	Toluene	0.3	3	25	91
9	3e	Xylene	0.3	3	25	90
10	3e	Dioxane	0.3	3	33	91
11	3e	THF	0.3	3	53	95
12	3e	^t BuOMe	0.3	3	46	93
13	3e	THF	0.3	0	-	-
14	3e	THF	0.3	1	57	95

15	3e	THF	0.3	6	45	93
16	3e	THF	0.15	1	67	95
17	3e	THF	0.075	1	70	95
18	3e	THF	-	1	64	94
19^c	3e	THF	0.075	1	66	96
20^d	3e	THF	0.075	1	79	95
21^e	3e	THF	0.075	1	53	93
22^f	3e	THF	0.075	1	63	93
22^g	3e	THF	0.075	1	76	94

^a Standard conditions: 0.1 mmol of **1a**, 0.5 mmol of a 70:30 *E*:*Z* mixture of **2a**, 0.3 mmol of H₂O and 0.01 mmol of catalyst **3** in 0.3 mL of solvent (0.3 M) were stirred at room temperature (25 °C) overnight (16 h). ^b Enantiomeric excess was measured by Supercritical Fluid Chromatography (SFC) using chiral columns. ^c 0.005 mmol of catalyst was used. ^d 0.02 mmol of catalyst was used. ^e 0.30 mmol of a 70:30 *E*:*Z* mixture of **2a** was used. ^f Reaction time was 64 hours. ^g **1o** was used instead of **1a**.

3. General procedure A: Addition of silyl dienol ethers to α -ketoesters



Catalyst **3e** (11.9 mg, 0.02 mmol, 0.2 equiv.) was added to a vial provided with a stir bar and it was dissolved in THF (75 μ L, 1.3 M). Then, α -ketoester **1a-o** (0.1 mmol, 1.0 equiv.) was added to the vial, followed by the corresponding silyl dienol ether **2a-b** (0.5 mmol, 5.0 equiv.) and water (2 μ L, 0.1 mmol, 1.0 equiv.). The solution was stirred overnight at room temperature. After that, the crude was concentrated *in vacuo* and purified by flash column chromatography as described in each case.

Ethyl (*R,E*)-2-hydroxy-6-oxo-2-phenylhex-4-enoate (**4a**)

Following the general procedure A; reaction between ethyl 2-oxo-2-phenylacetate **1a** (15.9 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4a** (79% yield, 95% ee) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -13.1$ (*c* 0.62, CHCl₃).

¹H-NMR: δ 9.45 (d, *J* = 7.9 Hz, 1H), 7.63 – 7.54 (m, 2H), 7.42 – 7.29 (m, 3H), 6.80 (ddd, *J* = 15.7, 7.6, 6.7 Hz, 1H), 6.17 (ddd, *J* = 15.7, 7.9, 1.2 Hz, 1H), 4.35 – 4.16 (m, 2H), 3.92 (s, 1H), 3.17 (ddd, *J* = 14.6, 7.6, 1.2 Hz, 1H), 3.07 (ddd, *J* = 14.6, 6.7, 1.2 Hz, 1H), 1.28 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.8, 174.1, 151.8, 140.8, 136.1, 128.7 (2C), 128.4, 125.4 (2C), 77.7, 63.2, 42.8, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₅O₃ [M-OH]⁺: 231.1016; found: 231.1001.

The enantiomeric excess was determined by SFC using a Chiralpak IG-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 4.41$ min, $\tau_{\text{major}} = 4.61$ min (2.5:97.5 *er*).

Ethyl (*R,E*)-2-hydroxy-6-oxo-2-(*p*-tolyl)hex-4-enoate (**4b**)

Following the general procedure A; reaction between ethyl 2-oxo-2-(*p*-tolyl)acetate **1b** (22.2 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave

product **4b** (58% yield, 92% *ee*) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -19.5$ (*c* 0.60, CHCl₃).

¹H-NMR: δ 9.45 (d, *J* = 7.9 Hz, 1H), 7.45 (d, *J* = 8.2 Hz, 2H), 7.18 (d, *J* = 8.2 Hz, 2H), 6.86 – 6.73 (m, 1H), 6.17 (dd, *J* = 15.7, 7.9 Hz, 1H), 4.35 – 4.15 (m, 2H), 3.86 (bs, 1H), 3.15 (dd, *J* = 14.7, 7.7 Hz, 1H), 3.05 (dd, *J* = 14.7, 6.6 Hz, 1H), 2.35 (s, 3H), 1.27 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.9, 174.3, 152.1, 138.3, 137.9, 136.1, 129.4 (2C), 125.4 (2C), 77.6, 63.1, 42.8, 21.12, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₅H₁₇O₃ [M-OH]⁺: 245.1172; found: 244.1192.

The enantiomeric excess was determined by SFC using a Chiralpak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.81$ min, $\tau_{\text{major}} = 3.11$ min (96:4 *er*).

Ethyl (R,E)-2-(4-(tert-butyl)phenyl)-2-hydroxy-6-oxohex-4-enoate (4c)

Following the general procedure A; reaction between ethyl 2-(4-(tert-butyl)phenyl)2-oxoacetate **1c** (28.1 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4c** (68% yield, 94% *ee*) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -12.8$ (*c* 0.80, CHCl₃).

¹H-NMR: δ 9.46 (d, *J* = 7.9 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 6.88 – 6.74 (m, 1H), 6.18 (dd, *J* = 15.7, 7.9 Hz, 1H), 4.36 – 4.15 (m, 2H), 3.85 (s, 1H), 3.16 (dd, *J* = 14.7, 7.9 Hz, 1H), 3.05 (dd, *J* = 14.7, 6.5 Hz, 1H), 1.32 (s, 9H), 1.28 (t, *J* = 7.2 Hz, 3H) ppm.

¹³C-NMR: δ 193.9, 174.2, 152.1, 151.4, 137.9, 136.0, 125.6 (2C), 125.1 (2C), 77.6, 63.1, 42.8, 34.7, 31.4 (3C), 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₈H₂₃O₃ [M-OH]⁺: 287.1642; found: 287.1670.

The enantiomeric excess was determined by SFC using a Chiralpak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.67$ min, $\tau_{\text{major}} = 3.00$ min (97:3 *er*).

Ethyl (R,E)-2-(4-chlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4d)

Following the general procedure A; reaction between ethyl 2-(4-chlorophenyl)2-oxoacetate **1d** (17.5 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4d** (80% yield, 95% *ee*) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -16.7$ (*c* 0.88, CHCl₃).

¹H-NMR: δ 9.45 (d, *J* = 7.8 Hz, 1H), 7.53 (d, *J* = 8.6 Hz, 2H), 7.34 (d, *J* = 8.6 Hz, 2H), 6.76 (ddd, *J* = 15.6, 7.7, 6.6 Hz, 1H), 6.16 (dd, *J* = 15.6, 7.8 Hz, 1H), 4.35 – 4.17 (m, 2H), 3.96 (bs, 1H), 3.13 (ddd, *J* = 14.7, 7.7, 1.3 Hz, 1H), 3.03 (ddd, *J* = 14.7, 6.6, 1.3 Hz, 1H), 1.27 (t, *J* = 7.1 Hz, 3H) ppm.


¹³C-NMR: δ 193.7, 173.8, 151.2, 139.2, 136.3, 134.5, 128.9 (2C), 127.1 (2C), 77.3, 63.4, 42.8, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₄ClO₃ [M-OH]⁺: 265.0626; found: 265.0653.

The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], τ_{minor} = 2.83 min, τ_{major} = 3.01 min (97.5:2.5 er).

The reaction was scaled up to 0.5 mmol scale. General procedure A was followed and product **4d** (102 mg, 72% yield, 96% ee) was obtained as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], τ_{minor} = 2.74 min, τ_{major} = 2.91 min (98:2 er).

Ethyl (*R,E*)-2-(4-bromophenyl)-2-hydroxy-6-oxohex-4-enoate (**4e**)



Following the general procedure A; reaction between ethyl 2-(4-bromophenyl)2-oxoacetate **1e** (16.5 μL, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL, 0.5 mmol) gave product **4e** (66% yield, 96% ee) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. [α]²⁵_D = -14.3 (c 0.84, CHCl₃).

¹H-NMR: δ 9.45 (d, *J* = 7.9 Hz, 1H), 7.54 – 7.43 (m, 4H), 6.75 (ddd, *J* = 15.7, 7.9, 6.7 Hz, 1H), 6.16 (ddd, *J* = 15.7, 7.9, 1.2 Hz, 1H), 4.36 – 4.16 (m, 2H), 3.96 (bs, 1H), 3.13 (ddd, *J* = 14.6, 7.9, 1.2 Hz, 1H), 3.02 (ddd, *J* = 14.6, 6.7, 1.2 Hz, 1H), 1.27 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.5, 173.5, 150.9, 139.6, 136.1, 131.7 (2C), 127.2 (2C), 122.5, 77.2, 63.3, 42.6, 14.1 ppm.


HRMS (ESI⁺): calculated for C₁₄H₁₄BrO₃ [M-OH]⁺: 309.0121; found: 309.0155.

The enantiomeric excess was determined by SFC using a Chiraldak IB-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], τ_{minor} = 1.33 min, τ_{major} = 1.52 min (98:2 er).

The reaction was scaled up to 0.5 mmol scale. General procedure A was followed and product **4e** (95 mg, 58% yield, 96% ee) was obtained as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. The enantiomeric excess was determined by SFC using a Chiraldak IB-3

column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 1.36$ min, $\tau_{\text{major}} = 1.54$ min (98:2 *er*).

Ethyl (*R,E*)-2-hydroxy-6-oxo-2-(4-(trifluoromethyl)phenyl)hex-4-enoate (4f)



Following the general procedure A; reaction between ethyl 2-oxo-2-(4-(trifluoromethyl)phenyl)acetate **1f** (20.0 μL , 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL , 0.5 mmol) gave product **4f** (72% yield, 95% *ee*) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_{\text{D}} = -15.2$ (*c* 0.88, CHCl_3).

$^1\text{H-NMR}$: δ 9.46 (d, $J = 7.8$ Hz, 1H), 7.74 (d, $J = 8.3$ Hz, 2H), 7.64 (d, $J = 8.3$ Hz, 2H), 6.76 (ddd, $J = 15.7, 7.6, 6.7$ Hz, 1H), 6.17 (ddt, $J = 15.7, 7.8, 1.2$ Hz, 1H), 4.37 – 4.17 (m, 2H), 4.01 (bs, 1H), 3.18 (ddd, $J = 14.7, 7.6, 1.2$ Hz, 1H), 3.05 (ddd, $J = 14.7, 6.7, 1.2$ Hz, 1H), 1.29 (t, $J = 7.1$ Hz, 3H) ppm.


$^{13}\text{C-NMR}$: δ 193.6, 173.5, 150.8, 144.6, 136.4, 130.7 (q, $J = 32.6$ Hz), 126.1 (2C), 125.7 (q, $J = 3.8$ Hz, 2C), 124.1 (q, $J = 272.3$ Hz), 77.5, 63.6, 42.9, 14.2 ppm.

$^{19}\text{F-NMR}$: δ -62.7 ppm.

HRMS (ESI $^+$): calculated for $\text{C}_{15}\text{H}_{14}\text{F}_3\text{O}_3$ [M-OH] $^+$: 299.0890; found: 299.0882.

The enantiomeric excess was determined by SFC using a Chiralpak IA column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.06$ min, $\tau_{\text{major}} = 2.27$ min (97.5:2.5 *er*).

Ethyl (*R,E*)-2-hydroxy-2-(3-methoxyphenyl)-6-oxohex-4-enoate (4g)



Following the general procedure A; reaction between ethyl 2-(3-methoxyphenyl)-2-oxoacetate **1g** (15.7 μL , 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL , 0.5 mmol) gave product **4g** (56% yield, 96% *ee*) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_{\text{D}} = -10.2$ (*c* 0.60, CHCl_3).


$^1\text{H-NMR}$: δ 9.45 (d, $J = 7.9$ Hz, 1H), 7.34 – 7.24 (m, 1H), 7.19 – 7.11 (m, 2H), 6.88 – 6.72 (m, 2H), 6.17 (ddt, $J = 15.7, 7.9, 1.2$ Hz, 1H), 4.35 – 4.17 (m, 2H), 3.88 (bs, 1H), 3.81 (s, 3H), 3.15 (ddd, $J = 14.7, 7.7, 1.2$ Hz, 1H), 3.05 (ddd, $J = 14.7, 6.6, 1.2$ Hz, 1H), 1.28 (t, $J = 7.1$ Hz, 3H) ppm.

$^{13}\text{C-NMR}$: δ 193.8, 174.0, 160.0, 151.8, 142.5, 136.1, 129.8, 117.7, 113.7, 111.5, 77.7, 63.2, 55.5, 42.8, 14.3 ppm.

HRMS (ESI $^+$): calculated for $\text{C}_{15}\text{H}_{17}\text{O}_4$ [M-OH] $^+$: 261.1121; found: 261.1132.

The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.99$ min, $\tau_{\text{major}} = 3.42$ min (98:2 *er*).

Ethyl (*R,E*)-2-(3-chlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4h)



Following the general procedure A; reaction between ethyl 2-(3-chlorophenyl)-2-oxoacetate **1h** (22.6 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4h** (82% yield, 95% *ee*) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_{\text{D}} = -16.7$ (*c* 0.86, CHCl₃).

¹H-NMR: δ 9.46 (d, *J* = 7.8 Hz, 1H), 7.61 (d, *J* = 0.7 Hz, 1H), 7.53 – 7.42 (m, 1H), 7.36 – 7.26 (m, 2H), 6.83 – 6.69 (m, 1H), 6.16 (ddt, *J* = 15.7, 7.8, 1.2 Hz, 1H), 4.37 – 4.18 (m, 2H), 3.96 (bs, 1H), 3.14 (ddd, *J* = 14.7, 7.6, 1.2 Hz, 1H), 3.03 (ddd, *J* = 14.7, 6.6, 1.2 Hz, 1H), 1.29 (t, *J* = 7.1 Hz, 3H) ppm.


¹³C-NMR: δ 193.7, 173.6, 151.1, 142.8, 136.3, 134.8, 130.0, 128.6, 125.9, 123.8, 77.3, 63.5, 42.8, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₄ClO₃ [M-OH]⁺: 265.0626; found: 265.0649.

The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.61$ min, $\tau_{\text{major}} = 2.85$ min (97:3 *er*).

The reaction was scaled up and performed on a 1.0 mmol scale. General procedure A was followed and product **4h** (226 mg, 79% yield, 96% *ee*) was obtained as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.56$ min, $\tau_{\text{major}} = 2.80$ min (98:2 *er*).

Ethyl (*R,E*)-2-(3,4-dichlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4i)



Following the general procedure A; reaction between ethyl 2-(3,4-dichlorophenyl)-2-oxoacetate **1i** (18.2 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4i** (73% yield, 95% *ee*) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_{\text{D}} = -13.8$ (*c* 0.93, CHCl₃).


¹H-NMR: δ 9.46 (d, *J* = 7.8 Hz, 1H), 7.75 – 7.69 (m, 1H), 7.49 – 7.39 (m, 2H), 6.74 (ddd, *J* = 15.7, 7.5, 6.7 Hz, 1H), 6.16 (ddt, *J* = 15.7, 7.8, 1.2 Hz, 1H), 4.38 – 4.18 (m, 2H), 3.99 (bs, 1H), 3.12 (ddd, *J* = 14.6, 7.5, 1.2 Hz, 1H), 3.00 (ddd, *J* = 14.7, 6.7, 1.2 Hz, 1H), 1.29 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.4, 173.2, 150.4, 140.8, 136.3, 132.9, 132.6, 130.5, 127.8, 125.0, 76.8, 63.5, 42.7, 14.1 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₃Cl₂O₃ [M-OH]⁺: 299.0236; found: 299.0240.

The enantiomeric excess was determined by SFC using a Chiralpak IB-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], τ_{minor} = 1.35 min, τ_{major} = 1.55 min (97.3:2.7 er).

Ethyl (R,E)-2-(2-bromophenyl)-2-hydroxy-6-oxohex-4-enoate (4j)

 Following the general procedure A; reaction between ethyl 2-(2-bromophenyl)-2-oxoacetate **1j** (21.5 μL, 0.1 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL, 0.5 mmol) gave product **4j** (66% yield, 82% ee) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. [α]²⁵_D = +10.3 (c 0.86, CHCl₃).


¹H-NMR: δ 9.48 (d, J = 7.9 Hz, 1H), 7.63 – 7.54 (m, 2H), 7.36 (td, J = 7.7, 1.3 Hz, 1H), 7.20 (td, J = 7.7, 1.6 Hz, 1H), 6.88 (ddd, J = 15.7, 7.4, 6.7 Hz, 1H), 6.16 (dd, J = 15.7, 7.9 Hz, 1H), 4.32 – 4.15 (m, 2H), 3.82 (bs, 1H), 3.34 (ddd, J = 14.7, 6.7, 1.2 Hz, 1H), 3.22 (ddd, J = 14.7, 7.4, 1.2 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.7, 173.1, 151.7, 139.7, 136.0, 134.9, 130.1, 128.1, 127.7, 122.0, 78.3, 62.9, 40.5, 14.2 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₄ClO₃ [M-OH]⁺: 309.0121; found: 309.0063.

The enantiomeric excess was determined by SFC using a Chiralpak ID-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], τ_{minor} = 1.51 min, τ_{major} = 1.69 min (91:9 er).

Ethyl (R,E)-2-hydroxy-2-(naphthalen-2-yl)-6-oxohex-4-enoate (4k)

 Following the general procedure A; reaction between ethyl 2-(naphthalen-2-yl)-2-oxoacetate **1k** (18 mg, 0.08 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (70.2 μL, 0.4 mmol) gave product **4k** (66% yield, 92% ee) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. [α]²⁵_D = -10.2 (c 0.60, CHCl₃).


¹H-NMR: δ 9.45 (d, J = 7.9 Hz, 1H), 8.17 – 8.04 (m, 1H), 7.95 – 7.79 (m, 3H), 7.72 – 7.62 (m, 1H), 7.60 – 7.46 (m, 2H), 6.83 (ddd, J = 15.7, 7.7, 6.6 Hz, 1H), 6.21 (dd, J = 15.7, 7.9 Hz, 1H), 4.45 – 4.17 (m, 2H), 4.05 (bs, 1H), 3.28 (ddd, J = 14.6, 7.7, 1.1 Hz, 1H), 3.19 (ddd, J = 14.6, 6.6, 1.1 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.8, 174.1, 151.7, 138.0, 136.2, 133.2, 133.1, 128.6 (2C), 127.7, 126.8, 126.7, 124.8, 123.2, 77.9, 63.3, 42.7, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₈H₁₇O₃ [M-OH]⁺: 281.1172; found: 281.1202.

The enantiomeric excess was determined by SFC using a Chiralpak IB-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 1.90$ min, $\tau_{\text{major}} = 2.80$ min (96:4 er).

Ethyl (R,E)-2-hydroxy-6-oxo-2-(thiophene-2-yl)hex-4-enoate (4l)



Following the general procedure A; reaction between ethyl 2-oxo-2-(thiophen-2-yl)acetate **1l** (14.4 μ L, 0.1 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4l** (83% yield, 94% ee) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -32.5$ (*c* 0.56, CHCl₃).


¹H-NMR: δ 9.47 (d, *J* = 7.9 Hz, 1H), 7.30 – 7.23 (m, 1H), 7.11 (dd, *J* = 3.6, 1.2 Hz, 1H), 6.99 (dd, *J* = 5.1, 3.6 Hz, 1H), 6.80 (dt, *J* = 15.7, 7.2 Hz, 1H), 6.17 (ddt, *J* = 15.7, 7.9, 1.2 Hz, 1H), 4.38 – 4.24 (m, 2H), 4.18 (bs, 1H), 3.13 (bs, 1H), 3.11 (bs, 1H), 1.31 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.7, 173.2, 150.8, 145.5, 136.3, 127.4, 125.8, 124.6, 76.5, 63.5, 44.0, 14.2 ppm.

HRMS (ESI⁺): calculated for C₁₂H₁₃O₃S [M-OH]⁺: 237.0580; found: 237.0628.

The enantiomeric excess was determined by SFC using a Chiralpak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.91$ min, $\tau_{\text{major}} = 3.09$ min (97:3 er).

Ethyl (R,E)-2-hydroxy-6-oxo-2-(pyridine-3-yl)hex-4-enoate (4m)



Following the general procedure A; reaction between ethyl 2-oxo-2-(pyridin-3-yl)acetate **1m** (17.9 mg, 0.1 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4m** (68% yield, 96% ee) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -13.6$ (*c* 0.57, CHCl₃).


¹H-NMR: δ 9.45 (d, *J* = 7.8 Hz, 1H), 8.86 (d, *J* = 2.2 Hz, 1H), 8.56 (dt, *J* = 4.8, 1.6 Hz, 1H), 7.93 (ddd, *J* = 7.9, 2.2, 1.6 Hz, 1H), 7.31 (dd, *J* = 7.9, 4.8 Hz, 1H), 6.83 – 6.70 (ddd, *J* = 15.8, 7.6, 6.7 Hz, 1H), 6.23 – 6.11 (ddt, *J* = 15.8, 7.8, 1.2 Hz, 1H), 4.37 – 4.16 (m, 2H), 3.17 (ddd, *J* = 14.6, 7.6, 1.2 Hz, 1H), 3.06 (ddd, *J* = 14.6, 6.7, 1.2 Hz, 1H), 1.28 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.5, 173.5, 150.5, 149.5, 147.4, 136.5, 136.5, 133.7, 123.5, 76.5, 63.7, 43.0, 14.2 ppm.

HRMS (ESI⁺): calculated for C₁₃H₁₆NO₄ [M+H]⁺: 250.1074; found: 250.1116.

The enantiomeric excess was determined by SFC using a Chiralpak IC column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], τ_{minor} = 4.09 min, τ_{major} = 5.06 min (2:98 er).

Ethyl (R,E)-2-hydroxy-6-oxo-2-((E)-styryl)hex-4-enoate (4n)

 Following the general procedure A; reaction between ethyl (E)-2-oxo-4-phenylbut-3-enoate **1n** (20.6 μL, 0.1 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL, 0.5 mmol) gave product **4n** (73% yield, 90% ee) as a slightly yellow oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. [α]²⁵_D = +11.0 (c 1.00, CHCl₃).


¹H-NMR: δ 9.50 (d, J = 7.9 Hz, 1H), 7.44 – 7.23 (m, 5H), 6.93 – 6.78 (m, 2H), 6.30 (d, J = 15.8 Hz, 1H), 6.19 (dd, J = 15.8, 7.9 Hz, 1H), 4.40 – 4.18 (m, 2H), 3.66 (s, 1H), 3.00 – 2.79 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 193.7, 174.1, 151.3, 136.1, 136.0, 131.4, 128.9 (2C), 128.7, 128.4, 127.0 (2C), 76.7, 63.1, 42.4, 14.4 ppm.

HRMS (ESI⁺): calculated for C₁₆H₁₇O₃ [M-OH]⁺: 257.1172; found: 257.1151.

The enantiomeric excess was determined by SFC using a Chiralpak IG-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], τ_{minor} = 4.76 min, τ_{major} = 6.17 min (95:5 er).

(R,E)-6,6,6-trifluoro-5-hydroxy-5-phenylhex-2-enal (4o)

 Following the general procedure A; reaction between 2,2,2-trifluoro-1-phenylethan-1-one **1o** (14 μL, 0.1 mmol) and 70:30 E:Z mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μL, 0.5 mmol) gave product **4o** (37% yield, 57% ee) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. [α]²⁵_D = -24.5 (c 0.188, CHCl₃).

¹H-NMR: δ 9.36 (d, J = 7.8 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.48 – 7.37 (m, 3H), 6.64 – 6.49 (m, 1H), 6.23 – 6.10 (m, 1H), 3.24 (dd, J = 15.3, 7.1 Hz, 1H), 3.09 (dd, J = 15.3, 7.3 Hz, 1H), 2.79 (s, 1H) ppm.


¹³C-NMR: δ 193.3, 149.3, 137.0, 135.6, 129.3 (2C), 128.9 (2C), 126.3 (q, J = 0.9 Hz), 125.3 (q, J = 285.9 Hz), 76.8 (q, J = 28.7 Hz), 39.1 ppm.

¹⁹F-NMR: δ -79.7 ppm.

HRMS (ESI⁺): calculated for C₁₂H₁₀F₃O [M-OH]⁺: 227.0678; found: 227.0648.

The enantiomeric excess was determined by SFC using a Chiraldak IA column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.21$ min, $\tau_{\text{major}} = 2.41$ min (21.6:78.4 *er*).

Ethyl (*R,E*)-2-hydroxy-4-methyl-6-oxo-2-phenylhex-4-enoate (4p)



Following the general procedure A; reaction between ethyl 2-oxo-2-phenylacetate **1a** (15.9 μ L, 0.1 mmol) and (*Z*)-trimethyl((3-methylbuta-1,3-dien-1-yl)oxy)silane **2b** (128.1 μ L, 0.5 mmol) gave product **4p** (65% yield, 90% *ee*) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -4.0$ (*c* 0.68, CHCl₃).


¹H-NMR: δ 9.96 (d, *J* = 8.0 Hz, 1H), 7.63 – 7.57 (m, 2H), 7.41 – 7.29 (m, 3H), 5.89 (d, *J* = 8.0 Hz, 1H), 4.32 – 4.20 (m, 2H), 3.87 (s, 1H), 3.12 (d, *J* = 13.7 Hz, 1H), 2.89 (d, *J* = 13.7 Hz, 1H), 2.19 (s, 3H), 1.29 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 191.1, 174.3, 158.7, 141.4, 131.1, 128.6 (2C), 128.3, 125.5 (2C), 78.5, 63.2, 49.6, 19.5, 14.2 ppm.

HRMS (ESI⁺): calculated for C₁₅H₁₇O₃ [M-OH]⁺: 245.1172 found: 245.1201.

The enantiomeric excess was determined by SFC using a Chiraldak IC column [CO₂/MeOH 95:5, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 9.43$ min, $\tau_{\text{major}} = 10.10$ min (95:5 *er*).

Methyl (*R,E*)-2-hydroxy-6-oxo-2-phenylhex-4-enoate (4q)



Following the general procedure A; reaction between methyl 2-oxo-2-phenylacetate **1q** (14.2 μ L, 0.1 mmol) and 70:30 *E:Z* mixture of (buta-1,3-dien-1-yloxy)trimethylsilane **2a** (87.7 μ L, 0.5 mmol) gave product **4q** (76% yield, 94% *ee*) as a colorless oil. Eluent: cyclohexane: ethyl acetate from 97:3 to 80:20. $[\alpha]^{25}_D = -4.7$ (*c* 0.74, CHCl₃).

¹H-NMR: δ 9.45 (d, *J* = 7.9 Hz, 1H), 7.62 – 7.53 (m, 2H), 7.44 – 7.31 (m, 3H), 6.78 (ddd, *J* = 15.6, 7.3, 6.7 Hz, 1H), 6.17 (dd, *J* = 15.7, 7.9 Hz, 1H), 3.84 (bs, 1H), 3.81 (s, 3H), 3.18 (dd, *J* = 14.6, 7.3 Hz, 1H), 3.08 (dd, *J* = 14.6, 6.7 Hz, 1H) ppm.

¹³C-NMR: δ 193.8, 174.6, 151.7, 140.6, 136.1, 128.8 (2C), 128.5 (2C), 125.4, 78.0, 53.8, 42.8 ppm.


HRMS (ESI⁺): calculated for C₁₃H₁₃O₃ [M-OH]⁺: 217.0859; found: 217.0877.

The enantiomeric excess was determined by SFC using a Chiraldak IG-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 4.61$ min, $\tau_{\text{major}} = 5.06$ min (3:97 *er*).

4. General procedure B: Synthesis of biologically active derivatives

4.1. Antifungal δ -lactone analog (7)

(*R,E*)-5-(4-bromophenyl)-6-ethoxy-5-hydroxy-6-oxohex-2-enoic acid (5)



To a solution of **4e** in MeCN/H₂O (6:1) at 0°C was added NaH₂PO₄·2H₂O (0.6 equiv.) followed by H₂O₂ (3.75 equiv.) and NaClO₂ (6.0 equiv.). It was stirred at room temperature overnight. Then, water was added to the reaction, phases were separated, and aqueous phase was extracted with ethyl acetate three times. Combined organic phase was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (cyclohexane: ethyl acetate/EtOH/AcOH (3/1/2%), gradient from 100:0 to 50:50) to give product **5** (84% yield, 95% ee) as a colorless oil. $[\alpha]^{25}_D = -19.0$ (*c* 1.23, CHCl₃).


¹H-NMR: δ 7.56 – 7.42 (m, 4H), 7.03 – 6.89 (m, 1H), 5.91 (d, *J* = 15.7 Hz, 1H), 4.37 – 4.15 (m, 2H), 3.05 (ddd, *J* = 14.5, 7.6, 1.0 Hz, 1H), 2.90 (ddd, *J* = 14.5, 6.9, 1.3 Hz, 1H), 1.28 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 173.8, 170.9, 145.1, 140.0, 131.8 (2C), 127.4 (2C), 124.8, 122.6, 77.4, 63.4, 42.6, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₉BrNO₅ [M+NH₄]⁺: 360.0441; found: 360.0395.

The enantiomeric excess was determined by SFC using a Chiralpak IA column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 3.87$ min, $\tau_{\text{major}} = 6.52$ min (97.5:2.5 *er*).

(R)-5-(4-bromophenyl)-6-ethoxy-5-hydroxy-6-oxohexanoic acid (6)



To a solution of **5** in THF/MeOH (1:1, 0.1 M) at 0°C was added NiCl₂·6H₂O (1.5 equiv.) followed by NaBH₄ (3.0 equiv.). It was stirred at the same temperature for 30 min, then the reaction was quenched with ammonium chloride (saturated aqueous solution). Organic solvents were evaporated under reduced pressure and the aqueous phase was extracted with ethyl acetate three times. Combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column

chromatography (cyclohexane: ethyl acetate/EtOH/AcOH (3/1/2%), gradient from 100:0 to 50:50) to give product **6** (79% yield, 95% ee) as a colorless oil. $[\alpha]^{25}_D = -3.3$ (*c* 0.72, CHCl₃).


¹H-NMR: δ 7.54 – 6.40 (m, 4H), 4.34 – 4.14 (m, 2H), 2.37 (t, *J* = 7.3 Hz, 2H), 2.25 – 2.12 (m, 1H), 2.11 – 1.97 (m, 1H), 1.80 – 1.52 (m, 2H), 1.26 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 179.6, 174.8, 140.7, 131.5 (2C), 127.6 (2C), 122.1, 77.9, 63.0, 38.9, 33.8, 19.1, 14.2 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₆BrO₄ [M-OH]⁺: 327.0226; found: 327.0172.

The enantiomeric excess was determined by SFC using a Chiraldak ID-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 1.75$ min, $\tau_{\text{major}} = 3.35$ min (97.5:2.5 *er*).

(R)-6-(4-bromophenyl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-2-one (**7**)



To a solution of **6** in THF:iPrOH (2:1, 2 M) at 0°C was added LiBH₄ (2.0 equiv.). It was stirred at room temperature overnight. Then, the reaction was quenched with HCl (1M aqueous solution). Organic solvent was evaporated under reduced pressure and the aqueous phase was extracted with ethyl acetate three times. Combined organic layers was dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Then, the residue was dissolved in dichloromethane (0.05M) with triethylamine (2.4 equiv.). It was slowly added to a solution of 2-chloro-1-methylpyridinium iodide (1.2 equiv.) in dichloromethane (0.2M). The reaction mixture was stirred at room temperature for 30 minutes. Water was added to the reaction, and it was extracted with dichloromethane four times. The combined organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (cyclohexane: ethyl acetate/EtOH/CH₃CO₂H (3/1/2%), gradient from 100:0 to 80:20) to give product **7** (45% yield, 96% ee) as a colorless solid. $[\alpha]^{25}_D = -7.4$ (*c* 1.09, CHCl₃).

¹H-NMR: δ 7.51 (d, *J* = 8.6 Hz, 2H), 7.22 (d, *J* = 8.6 Hz, 2H), 3.75 (d, *J* = 12.2 Hz, 1H), 3.65 (d, *J* = 12.2 Hz, 1H), 2.52 – 2.43 (m, 2H), 2.36 (ddd, *J* = 14.3, 12.5, 4.4 Hz, 1H), 2.18 (dt, *J* = 14.3, 4.3 Hz, 1H), 1.91 – 1.78 (m, 1H), 1.68 – 1.51 (m, 1H) ppm.


¹³C-NMR: δ 171.3, 139.7, 132.2 (2C), 127.3 (2C), 122.5, 88.1, 70.1, 29.5, 28.1, 16.1 ppm.

HRMS (ESI⁺): calculated for C₁₂H₁₄BrO₃ [M-H]⁺: 285.0121; found: 285.0100.

The enantiomeric excess was determined by SFC using a Chiraldak ID-3 column [CO₂/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 2.24$ min, $\tau_{\text{major}} = 2.42$ min (98:2 *er*).

4.2. Inhibitor of neuropathic pain (10)

Ethyl (R)-(3-chlorophenyl)-2,6-dihydroxyhexanoate (8)



To a solution of **4h** in THF/MeOH (1:1, 0.1 M) at 0°C was added NiCl₂·6H₂O (1.5 equiv.) followed by NaBH₄ (3.0 equiv.). It was stirred at the same temperature for 15 min, then the reaction was quenched with ammonium chloride (saturated aqueous solution). Organic solvents were evaporated under reduced pressure and the aqueous phase was extracted with ethyl acetate three times. Combined organic layer was dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (cyclohexane: ethyl acetate, gradient from 100:0 to 50:50) to give product **8** (60% yield, >98% ee) as a colorless oil. $[\alpha]^{25}_D = -23.9$ (c 1.0, CHCl₃).


¹H-NMR: δ 7.63 – 7.60 (m, 1H), 7.50 – 7.45 (m, 1H), 7.28 – 7.25 (m, 2H), 4.35 – 4.16 (m, 2H), 3.63 (t, J = 6.4 Hz, 2H), 2.23 – 2.10 (m, 1H), 2.06 – 1.93 (m, 1H), 1.63 – 1.52 (m, 2H), 1.52 – 1.32 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 174.9, 144.1, 134.5, 129.7, 128.0, 126.1, 124.0, 78.1, 63.0, 62.8, 39.7, 32.7, 20.1, 14.3 ppm.

HRMS (ESI⁺): calculated for C₁₄H₁₈ClO₃ [M-OH]⁺: 269.0939; found: 269.0991.

The enantiomeric excess was determined by SFC using a Chiralpak IA column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 3.0 mL/min], $\tau_{\text{minor}} = 2.95$ min, $\tau_{\text{major}} = 3.07$ min (<2:>98 er).

Ethyl (R)-6-(benzyloxy)-2-(3-chlorophenyl)-2-hydroxyhexanoate (9)



A stirred suspension of **8** (0.1 mmol), MgO (2 equiv.) and 2-benzyloxy-1-methylpyridinium triflate (2 equiv.) in trifluorotoluene (0.05 M) was heated at 85°C overnight. Afterwards, the mixture was cooled to room temperature and concentrated under reduced pressure. The crude was purified by silica gel chromatography (cyclohexane: ethyl acetate, gradient from 100:0 to 50:50) and product **9** was obtained as a colorless oil (62% yield, 95% ee). $[\alpha]^{25}_D = -18.2$ (*c* 1.12, CHCl₃).


¹H-NMR: δ 7.64 – 7.59 (m, 1H), 7.51 – 7.45 (m, 1H), 7.38 – 7.24 (m, 7H), 4.48 (s, 2H), 4.33 – 4.15 (m, 2H), 3.82 (s, 1H), 3.45 (t, J = 6.4 Hz, 2H), 2.25 – 2.08 (m, 1H), 2.07 – 1.92 (m, 1H), 1.70 – 1.56 (m, 2H), 1.52 – 1.33 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H) ppm.

¹³C-NMR: δ 174.9, 144.2, 138.7, 134.4, 129.6, 128.5 (2C), 128.0, 127.8 (2C), 127.7, 126.2, 124.0, 78.1, 73.1, 70.3, 62.9, 39.8, 29.8, 20.6, 14.3 ppm.

HRMS (ESI⁺): calculated for C₂₁H₂₄ClO₃ [M-OH]⁺: 359.1408; found: 359.1458.

The enantiomeric excess was determined by SFC using a Chiraldak IB-3 column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 1.60$ min, $\tau_{\text{major}} = 2.68$ min (97:3 er).

(R)-6-(benzyloxy)-2-(3-chlorophenyl)-2-hydroxyhexanamide (10)



7N ammonia solution in methanol (1 mL) was added to product **9** (0.07 mmol) and the reaction was stirred at 80°C overnight. Then, reaction mixture was concentrated under reduced pressure and purified by flash column chromatography (cyclohexane: ethyl acetate, gradient from 100:0 to 25:75) to give product **10** (68% yield, >98% ee) as a colorless oil. $[\alpha]^{25}_D = -3.7$ (*c* 0.27, CHCl₃).

¹H-NMR: δ 7.63 – 7.58 (m, 1H), 7.50 – 7.43 (m, 1H), 7.38 – 7.28 (m, 5H), 7.26 – 7.24 (m, 2H), 6.54 (bs, 1H), 5.39 (bs, 1H), 4.49 (s, 2H), 3.85 (s, 1H), 3.53 (t, $J = 5.9$ Hz, 2H), 2.33 – 2.20 (m, 1H), 2.14 – 2.02 (m, 1H), 1.74 – 1.63 (m, 2H), 1.56 – 1.37 (m, 2H) ppm.


¹³C-NMR: δ 176.4, 144.7, 138.1, 134.5, 129.7, 128.7 (2C), 128.1 (2C), 128.0, 127.9, 125.9, 123.9, 78.9, 73.4, 70.5, 38.6, 29.1, 21.1 ppm.


HRMS (ESI⁺): calculated for C₁₉H₂₃ClNO₃ [M+H]⁺: 348.1361; found: 348.1330.

The enantiomeric excess was determined by SFC using a Chiraldak IB-3 column [CO_2/MeOH from 95:5 to 60:40 in 8 min, flow rate 2.0 mL/min], $\tau_{\text{minor}} = 3.50$ min, $\tau_{\text{major}} = 6.52$ min (>98:<2 er).


5. NMR spectra and SFC chromatograms


Ethyl (*R,E*)-2-hydroxy-6-oxo-2-phenylhex-4-enoate (4a)







Ethyl (R,E)-2-hydroxy-6-oxo-2-(*p*-tolyl)hex-4-enoate (4b)










Ethyl (*R,E*)-2-(4-(*tert*-butyl)phenyl)-2-hydroxy-6-oxohex-4-enoate (4c)







Ethyl (*R,E*)-2-(4-chlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4d)










- 0.5 mmol scale chromatogram:





Ethyl (*R,E*)-2-(4-bromophenyl)-2-hydroxy-6-oxohex-4-enoate (4e)








- 0.5 mmol scale chromatogram:





Ethyl (*R,E*)-2-hydroxy-6-oxo-2-(4-(trifluoromethyl)phenyl)hex-4-enoate (4f)







Ethyl (*R,E*)-2-hydroxy-2-(3-methoxyphenyl)-6-oxohex-4-enoate (4g)






Ethyl (*R,E*)-2-(3-chlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4h)







- 1.0 mmol scale chromatogram:




Ethyl (*R,E*)-2-(3,4-dichlorophenyl)-2-hydroxy-6-oxohex-4-enoate (4i)







Ethyl (*R,E*)-2-(2-bromophenyl)-2-hydroxy-6-oxohex-4-enoate (4j)










Ethyl (*R,E*)-2-hydroxy-2-(naphthalen-2-yl)-6-oxohex-4-enoate (4k)







Ethyl (*R,E*)-2-hydroxy-6-oxo-2-(thiophene-2-yl)hex-4-enoate (4l)







Ethyl (*R,E*)-2-hydroxy-6-oxo-2-(pyridine-3-yl)hex-4-enoate (4m)








Ethyl (*R,E*)-2-hydroxy-6-oxo-2-((*E*)-styryl)hex-4-enoate (4n)






(R,E)-6,6,6-trifluoro-5-hydroxy-5-phenylhex-2-enal (4o)







File Information						
LC-File	R0651A-nac-F1-2021-09-2303-18-32.D	#	Time	Type	Area	Height
File Path	D:\DATOS\UAL305\2021-09-22\15-17-33\R0651A-nac-F1-2021-09-2303-18-32.D					
Date	23-Sep-21, 03:21:59					
Sample	R0651A-nac-F1					
Sample Info	R0651A-nac-F1					
Barcode						
Operator	SYSTEM					
Method	[A]-gradient5_40_MeOH_MS.M					
Reference	D:\DATOS\UAL305\2021-09-22\15-17-33\no Sample Name\2021-09-					
Analysis Time	7.993 min					
Scanning Rate	10.0007 min / 0.407 sec, 12000 datapoints					



File Information						
LC-File	R0651A-F1-OP-2021-09-21-17-47-48.D	#	Time	Type	Area	Height
File Path	D:\DATOS\UAL305\2021-09-21\17-47-48					
Date	21-Sep-21, 18:02:29					
Sample	R0651A-F1-OP					
Sample Info	R0651A-F1-OP					
Barcode						
Operator	SYSTEM					
Method	[A]-gradient5_40_MeOH_MS.M					
Reference	D:\DATOS\UAL305\2021-09-21\17-47-48\no Sample Name\2021-09-					
Analysis Time	7.993 min					
Scanning Rate	10.0007 min / 0.407 sec, 12000 datapoints					


Ethyl (*R,E*)-2-hydroxy-4-methyl-6-oxo-2-phenylhex-4-enoate (4p)





File Information


LC File	RR389A_RAC2021-02-1305-21-17.D
File Path	D:\DATOS\UL305\2021-02-12 18-06-26
Date	13-Feb-21, 09:23:49
Sample	RR389A_RAC
Sample Info	RR389A_RAC
Barcode	
Operator	SYSTEM
Method	IC-2-5-30_MeOH_H2O_MS.M
Reference	D:\DATOS\UL305\2021-02-12 18-06-26\no Sample Name2021-02-
Analysis Time	> 991 min




File Information


LC File	RR389B_OP2021-02-1511-51-02.D
File Path	D:\DATOS\UL305\2021-02-15 11-00-49
Date	15-Feb-21, 11:53:22
Sample	RR389B_OP
Sample Info	RR389B_OP
Barcode	
Operator	SYSTEM
Method	IC-2-5-15_MeOH_H2O_MS.M
Reference	D:\DATOS\UL305\2021-02-15 11-00-49\no Sample Name2021-02-
Analysis Time	> 991 min


Methyl (*R,E*)-2-hydroxy-6-oxo-2-phenylhex-4-enoate (4q)







(*R,E*)-5-(4-bromophenyl)-6-ethoxy-5-hydroxy-6-oxohex-2-enoic acid (5)







(R)-5-(4-bromophenyl)-6-ethoxy-5-hydroxy-6-oxohexanoic acid (6)







(*R*)-6-(4-bromophenyl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-2-one (7)







Ethyl (R)-(3-chlorophenyl)-2,6-dihydroxyhexanoate (8)







Ethyl (R)-6-(benzyloxy)-2-(3-chlorophenyl)-2-hydroxyhexanoate (9)






(R)-6-(benzyloxy)-2-(3-chlorophenyl)-2-hydroxyhexanamide (10)





6. Single Crystal X-Ray Structure of δ -lactone 7



CCDC 2101111

A clear colourless prismatic-like specimen of $C_{12}H_{13}BrO_3$, approximate dimensions 0.065 mm x 0.192 mm x 0.218 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured on a Bruker Kappa Apex II Bruker APEX-II CCD system ($Mo\text{ K}\alpha$, $\lambda = 0.71073 \text{ \AA}$).

The total exposure time was 20.28 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using a monoclinic unit cell yielded a total of 22324 reflections to a maximum θ angle of 25.35° (0.83 \AA resolution), of which 2111 were independent (average redundancy 10.575, completeness = 99.8%, $R_{\text{int}} = 3.09\%$, $R_{\text{sig}} = 1.92\%$) and 2051 (97.16%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 8.3815(2) \text{ \AA}$, $b = 7.13240(10) \text{ \AA}$, $c = 10.0251(2) \text{ \AA}$, $\beta = 103.8320(10)^\circ$, volume = $581.92(2) \text{ \AA}^3$, are based upon the refinement of the XYZ-centroids of 9956 reflections above $20 \sigma(I)$ with $5.005^\circ < 2\theta < 52.29^\circ$. Data were corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.819. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.5140 and 0.8030.

The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P 1 21 1, with $Z = 2$ for the formula unit, $C_{12}H_{13}BrO_3$. The final anisotropic full-matrix least-squares refinement on F^2 with 146 variables converged at $R1 = 1.83\%$, for the observed data and $wR2 = 5.47\%$ for all data. The goodness-of-fit was 1.183. The largest peak in the final difference electron density synthesis was $0.317 \text{ e}^-/\text{\AA}^3$ and the largest hole was $-0.295 \text{ e}^-/\text{\AA}^3$ with an RMS deviation of $0.052 \text{ e}^-/\text{\AA}^3$. On the basis of the final model, the calculated density was 1.627 g/cm^3 and $F(000)$, 288 e^- .

Table 1. Sample and crystal data.

Identification code	03363
Chemical formula	C ₁₂ H ₁₃ BrO ₃
Formula weight	285.13 g/mol
Temperature	200(2) K
Wavelength	0.71073 Å
Crystal size	0.065 x 0.192 x 0.218 mm
Crystal habit	clear colourless prismatic
Crystal system	monoclinic
Space group	P 1 21 1
Unit cell dimensions	a = 8.3815(2) Å α = 90° b = 7.13240(10) Å β = 103.8320(10)° c = 10.0251(2) Å γ = 90°
Volume	581.92(2) Å ³
Z	2
Density (calculated)	1.627 g/cm ³
Absorption coefficient	3.521 mm ⁻¹
F(000)	288

Table 2. Data collection and structure refinement.

Diffractometer	Bruker Kappa Apex II Bruker APEX-II CCD
Theta range for data collection	2.09 to 25.35°
Index ranges	-10<=h<=10, -8<=k<=8, -12<=l<=12
Reflections collected	22324
Independent reflections	2111 [R(int) = 0.0309]
Coverage of independent reflections	99.8%
Absorption correction	multi-scan
Max. and min. transmission	0.8030 and 0.5140
Structure solution technique	direct methods
Structure solution program	SHELXS-97 (Sheldrick 2008)
Refinement method	Full-matrix least-squares on F ²
Refinement program	SHELXL-2018/3 (Sheldrick, 2018)
Function minimized	Σ w(F _o ² - F _c ²) ²
Data / restraints / parameters	2111 / 1 / 146
Goodness-of-fit on F²	1.183
Final R indices	2051 data; I>2σ(I) R1 = 0.0183, wR2 = 0.0462 all data R1 = 0.0195, wR2 = 0.0547
Weighting scheme	w=1/[σ ² (F _o ²)+(0.0223P) ² +0.1857P] where P=(F _o ² +2F _c ²)/3
Absolute structure parameter	0.016(4)
Largest diff. peak and hole	0.317 and -0.295 eÅ ⁻³
R.M.S. deviation from mean	0.052 eÅ ⁻³

Table 3. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å²).U(eq) is defined as one third of the trace of the orthogonalized U_{ij} tensor.

	x/a	y/b	z/c	U(eq)
Br1	0.87779(4)	0.01906(8)	0.76130(4)	0.05028(14)
C1	0.5415(5)	0.5982(5)	0.5775(4)	0.0352(8)
C2	0.6765(4)	0.4976(8)	0.6758(4)	0.0452(9)
C3	0.6415(5)	0.4464(6)	0.8137(4)	0.0440(9)
C4	0.5517(5)	0.6081(6)	0.8614(4)	0.0389(8)
C5	0.3895(4)	0.6466(5)	0.7595(3)	0.0314(7)
C6	0.2634(4)	0.4928(6)	0.7566(3)	0.0290(7)
C7	0.2164(5)	0.4458(5)	0.8772(4)	0.0396(9)
C8	0.1021(5)	0.3060(6)	0.8787(4)	0.0405(9)
C9	0.0334(4)	0.2123(5)	0.7586(4)	0.0347(8)
C10	0.0741(5)	0.2565(5)	0.6380(4)	0.0384(8)
C11	0.1887(5)	0.3964(5)	0.6375(3)	0.0344(8)
C12	0.3177(5)	0.8357(5)	0.7864(4)	0.0416(9)
O1	0.4132(3)	0.6681(4)	0.6196(2)	0.0338(5)
O2	0.5421(4)	0.6257(5)	0.4588(3)	0.0554(8)
O3	0.4306(4)	0.9853(4)	0.7963(3)	0.0520(8)

Table 4. Bond lengths (Å).

Br1-C9	1.902(4)	C1-O2	1.208(5)
C1-O1	1.341(4)	C1-C2	1.495(6)
C2-C3	1.525(6)	C3-C4	1.516(5)
C4-C5	1.517(5)	C5-O1	1.471(4)
C5-C6	1.519(5)	C5-C12	1.527(5)
C6-C11	1.390(5)	C6-C7	1.400(5)
C7-C8	1.385(5)	C8-C9	1.377(5)
C9-C10	1.370(5)	C10-C11	1.386(5)
C12-O3	1.414(5)		

Table 5. Bond angles (°).

O2-C1-O1	116.3(4)	O2-C1-C2	123.1(3)
O1-C1-C2	120.6(3)	C1-C2-C3	115.7(3)
C4-C3-C2	108.7(3)	C3-C4-C5	111.0(3)
O1-C5-C4	110.9(3)	O1-C5-C6	108.0(3)
C4-C5-C6	112.9(3)	O1-C5-C12	103.0(3)
C4-C5-C12	111.6(3)	C6-C5-C12	109.9(3)
C11-C6-C7	117.5(3)	C11-C6-C5	122.8(3)
C7-C6-C5	119.7(3)	C8-C7-C6	121.3(3)
C9-C8-C7	119.0(3)	C10-C9-C8	121.3(4)

C10-C9-Br1	119.7(3)	C8-C9-Br1	119.0(3)
C9-C10-C11	119.2(3)	C10-C11-C6	121.5(3)
O3-C12-C5	113.2(3)	C1-O1-C5	124.2(3)

Table 6. Torsion angles (°).

O2-C1-C2-C3	-169.8(4)	O1-C1-C2-C3	12.0(6)
C1-C2-C3-C4	-40.2(5)	C2-C3-C4-C5	60.7(4)
C3-C4-C5-O1	-51.8(4)	C3-C4-C5-C6	69.6(4)
C3-C4-C5-C12	-166.0(3)	O1-C5-C6-C11	-0.3(4)
C4-C5-C6-C11	-123.3(4)	C12-C5-C6-C11	111.4(4)
O1-C5-C6-C7	-179.1(3)	C4-C5-C6-C7	57.9(4)
C12-C5-C6-C7	-67.4(4)	C11-C6-C7-C8	1.3(6)
C5-C6-C7-C8	-179.8(3)	C6-C7-C8-C9	-0.2(6)
C7-C8-C9-C10	-1.0(6)	C7-C8-C9-Br1	179.5(3)
C8-C9-C10-C11	1.1(6)	Br1-C9-C10-C11	-179.5(3)
C9-C10-C11-C6	0.1(5)	C7-C6-C11-C10	-1.2(5)
C5-C6-C11-C10	180.0(3)	O1-C5-C12-O3	-67.6(4)
C4-C5-C12-O3	51.5(4)	C6-C5-C12-O3	177.5(3)
O2-C1-O1-C5	179.0(3)	C2-C1-O1-C5	-2.7(5)
C4-C5-O1-C1	22.6(5)	C6-C5-O1-C1	-101.6(3)
C12-C5-O1-C1	142.2(3)		

Table 7. Anisotropic atomic displacement parameters (\AA^2).

The anisotropic atomic displacement factor exponent takes the form:

$$-2\pi^2 [h^2 a^{*2} U_{11} + \dots + 2 h k a^* b^* U_{12}]$$

	U₁₁	U₂₂	U₃₃	U₂₃	U₁₃	U₁₂
Br1	0.0513(2)	0.0494(2)	0.0521(2)	0.0025(3)	0.01619(15)	-0.0112(2)
C1	0.044(2)	0.0279(16)	0.039(2)	-0.0066(14)	0.0189(16)	-0.0050(15)
C2	0.0401(18)	0.041(3)	0.057(2)	-0.005(2)	0.0174(15)	0.005(2)
C3	0.039(2)	0.045(2)	0.044(2)	0.0061(16)	0.0013(17)	0.0060(17)
C4	0.037(2)	0.046(2)	0.0316(19)	0.0013(16)	0.0039(16)	-0.0019(17)
C5	0.0374(19)	0.0349(19)	0.0238(16)	0.0002(14)	0.0110(14)	0.0026(15)
C6	0.0324(14)	0.030(2)	0.0253(13)	0.0022(15)	0.0082(11)	0.0050(15)
C7	0.045(2)	0.047(2)	0.0274(17)	-0.0024(14)	0.0098(15)	-0.0045(16)
C8	0.044(2)	0.050(2)	0.0292(18)	0.0028(16)	0.0130(16)	-0.0021(18)
C9	0.0331(18)	0.0336(19)	0.0379(19)	0.0042(15)	0.0094(15)	0.0036(15)
C10	0.042(2)	0.042(2)	0.0304(18)	-0.0036(16)	0.0067(15)	-0.0014(17)
C11	0.0403(19)	0.0374(19)	0.0269(16)	0.0026(15)	0.0107(14)	0.0038(16)
C12	0.058(2)	0.035(2)	0.037(2)	-0.0006(16)	0.0218(18)	0.0056(18)
O1	0.0397(13)	0.0391(14)	0.0258(12)	0.0041(10)	0.0140(10)	0.0051(11)
O2	0.074(2)	0.0593(18)	0.0430(17)	0.0029(14)	0.0347(15)	0.0073(16)
O3	0.0842(19)	0.035(2)	0.0406(13)	-0.0050(13)	0.0234(13)	-0.0090(15)

Table 8. Hydrogen atomic coordinates and isotropic atomic displacement parameters (\AA^2).

	x/a	y/b	z/c	U(eq)
H2A	0.7762	0.5771	0.6932	0.054
H2B	0.7015	0.3809	0.6313	0.054
H3A	0.5732	0.3316	0.8040	0.053
H3B	0.7458	0.4215	0.8821	0.053
H4A	0.6212	0.7219	0.8718	0.047
H4B	0.5310	0.5778	0.9522	0.047
H7	0.2637	0.5112	0.9597	0.048
H8	0.0716	0.2752	0.9614	0.049
H10	0.0243	0.1920	0.5556	0.046
H11	0.2169	0.4272	0.5538	0.041
H12A	0.2202	0.8626	0.7111	0.05
H12B	0.2808	0.8280	0.8729	0.05
H3O	0.4352	1.0194	0.7171	0.078

Table 9. Hydrogen bond distances (\AA) and angles ($^\circ$).

	Donor-H	Acceptor-H	Donor-Acceptor Angle	
C2-H2B···Br1#1	0.99	3.10	3.813(5)	129.8
C4-H4B···O3#2	0.99	2.55	3.510(5)	163.0
O3-H3O···O2#3	0.84	1.97	2.806(4)	173.5